Danish researchers examined data from over 77,000 people taking anti-obesity medications without diabetes. They discovered that 52 percent stopped treatment within one year. Eighteen percent quit after three months, 31 percent after six months, and 42 percent within nine months. People under 30 were 48 percent more likely to stop than adults aged 45 to 59. Men and people with chronic conditions also showed higher dropout rates.
Cost Pressures Limit Long-Term Use
Patients living in low-income areas were 14 percent more likely to discontinue the medications compared to those in wealthier communities. The high price of the drugs may explain this trend. In Denmark, a month’s supply of Ozempic can cost €313, while in Germany, the same treatment costs about €120. Since government support often excludes non-diabetic patients, many people face financial barriers to continuing therapy.
Long-Term Commitment Remains Essential
Ozempic and Wegovy belong to a class of drugs called GLP-1 receptor agonists. These medications mimic a hormone that lowers appetite and supports weight loss. Researchers warned that quitting treatment usually results in regaining lost weight. “The benefits disappear once people stop the drugs,” said Reimar W. Thomsen, professor of metabolic disease epidemiology at Aarhus University. He emphasized the importance of long-term adherence to secure positive outcomes.
Supporting Patients for Better Results
Researchers noted that people who had previously taken psychiatric or gastrointestinal medications faced a higher risk of stopping, possibly due to side effects such as nausea or vomiting. The findings will be presented at the European Association for the Study of Diabetes conference in Vienna. Thomsen argued that stronger support systems could help patients remain on treatment. He stressed that improved adherence could lower risks of heart disease, addiction, and cancer while improving overall quality of life.
